# Recordati account plan

> Recordati is a Milan-based pharmaceutical group in rare diseases and specialty and primary care, with EUR 2,618.4 million of FY 2025 revenue.

## At a glance

Recordati is a Milan-headquartered pharmaceutical group that combines a Specialty & Primary Care business (urology, cardiovascular, gastro-intestinal, cough and cold, consumer brands) with a global Rare Diseases business in endocrinology, hema-oncology and metabolic disorders. It is present in around 150 countries and had 4,693 employees at year-end 2025. FY 2025 net revenue was EUR 2,618.4 million (+11.8%), EBITDA EUR 991.1 million (37.8% margin) and net income EUR 443.6 million. A tender offer by CVC Fund IX and GBL closed on 9 November 2026 with about 91.451% of the capital, and a squeeze-out and delisting from Euronext Milan were expected by the end of November 2026; the company is now under the management and coordination of Respighi TopCo S.à r.l.

## Business units

- **Specialty & Primary Care** (58.7% of FY 2025 revenue (EUR 1,477.9 million excluding pharmaceutical chemicals)): Prescription and OTC/consumer brands in urology, cardiovascular, gastro-intestinal, cough and cold and other areas, sold through subsidiaries across Europe, Russia/CIS, Türkiye and North Africa. Revenue grew 2.0% in FY 2025 and was EUR 1,135.5 million (+0.5%) in the first nine months of 2026, with the Cardicor licence loss offset by Vazkepa. Led by Alberto Martinez, Executive VP Specialty & Primary Care.
- **Rare Diseases** (41.3% of FY 2025 revenue (EUR 1,081.4 million)): Treatments in endocrinology (Isturisa, Signifor), hema-oncology (Enjaymo, Qarziba, Sylvant) and metabolic disorders (Carbaglu, Panhematin, Cystadrops), sold worldwide and the only business the group runs in the US. Revenue grew 29.7% in FY 2025 and reached EUR 928.2 million (+18.7%) in the first nine months of 2026. Led by Scott Pescatore, Executive VP Rare Diseases.
- **Pharmaceutical chemicals** (2.3% of FY 2025 revenue (EUR 59.1 million)): Active ingredients made at Campoverde di Aprilia (Italy) and Cork (Ireland), mainly for the group's own drugs, with residual capacity sold to third parties in highly regulated markets. Reported within Specialty & Primary Care.

## Strategic priorities

- **2025-2027 Three-Year Plan targets**: The plan approved in April 2025 targets FY 2027 net revenue of EUR 3,000-3,200 million, EBITDA of EUR 1,140-1,225 million and adjusted net income of EUR 770-820 million, excluding any US tariff or most-favoured-nation pricing impact.
- **Isturisa growth in the US**: After the April 2025 US label expansion to Cushing's syndrome, Isturisa peak year sales are estimated above EUR 1.2 billion. The US field force and MSL team were expanded to reach non-overt patients, who were around 20% of the treated population in Q1 2026.
- **Bolt-on business development and M&A**: Capital allocation combines a progressive dividend with bolt-on M&A and licensing; 2025-2026 deals brought in Vazkepa (Amarin), Inrebic for Japan, mRNA-3927 (Moderna) and zilganersen (Ionis).
- **Rare disease pipeline and lifecycle management**: Pasireotide in post-bariatric hypoglycaemia met its Phase 2 endpoint, sutimlimab enters a pivotal Phase 3 in chronic ITP at the beginning of 2027, and an Isturisa Phase IV began in August 2026. The group says it will not do discovery or very high-risk R&D.
- **One company culture and digitalisation**: Organisational priorities include simplification, digitalisation and harmonised ways of working, new IT systems for the digitalisation roadmap, and increasing use of AI in real-world evidence and clinical development.

## Latest results

In the first nine months of 2026 net revenue was EUR 2,103.7 million, up 7.5% (+9.4% like-for-like at constant exchange rates), and EBITDA EUR 801.1 million at a 38.1% margin. Rare Diseases grew 18.7% to EUR 928.2 million, led by Isturisa (EUR 285.9 million, +54.8%) and Enjaymo (EUR 135.2 million, +30.0%), while Specialty & Primary Care was EUR 1,135.5 million (+0.5%). Free cash flow was EUR 459.8 million and net debt fell to EUR 1,697.8 million, around 1.6x EBITDA. FY 2026 guidance (revenue EUR 2,730-2,800 million, EBITDA EUR 995-1,030 million) was confirmed, with the group expecting the upper end of the ranges.

## Investments and deals

- **mRNA-3927 licence from Moderna**: Licensed on 29 January 2026 for propionic acidemia, with a US$ 50 million upfront and up to US$ 110 million in near-term milestones; data readout expected by end-2026.
- **Vazkepa licence from Amarin**: Licensed in June 2025 for 59 countries focused on Europe (upfront US$ 25 million); expected to exceed EUR 40 million in revenues in 2027.
- **Inrebic and zilganersen licences**: Inrebic was in-licensed for Japan (upfront US$ 11 million), with launch expected mid-2026; zilganersen for Alexander disease was licensed from Ionis outside the US on 25 June 2026.
- **Isturisa commercial investment**: An extra EUR 40-50 million of Isturisa investment in 2026, reaching full speed in the second half, funds the expanded US customer-facing teams.
- **Manufacturing footprint changes**: Pardubice ceased production on 31 December 2025; Campoverde is undergoing an industrial transformation including a photovoltaic plant of approximately 10 MWp.

## Challenges and risks

- **Currency headwinds**: Adverse FX cost EUR 64.2 million in FY 2025, mainly the Turkish lira and the US dollar, and FY 2026 guidance assumes an FX headwind of about -3.5%.
- **Pricing and access pressure**: Isturisa was refused national reimbursement in China, leading to the liquidation of the Chinese rare diseases subsidiary, and Türkiye approved no price increase in 2025.
- **Flat Specialty & Primary Care**: SPC was flat in 2026 on the loss of the Cardicor licence in Italy and weaker cough and cold seasons; Italy fell 8.5% and Germany 6.6% in H1 2026.
- **US tariff and pricing exposure**: Targets exclude US tariffs and most-favoured-nation pricing; US inventory was built ahead of potential tariffs to cover the majority of 2026 sales.
- **Supply chain and geopolitical risk**: The risk catalogue names geopolitical exposure (Russia, Türkiye, sanctions), manufacturing and supply-chain disruption across over 150 contract manufacturers, and cyber risk.

## What leadership says

> "Our Rare Diseases franchise remains a key driver of growth, supported by strong momentum across our portfolio, particularly Isturisa® in the U.S., and continued progress in advancing our pipeline." — Rob Koremans, Chief Executive Officer, First Nine Months 2026 Results press release, 2026-11-10

> "we will not start to do discovery or very high-risk R&D" — Rob Koremans, Chief Executive Officer, Full Year 2025 Results Conference Call, 2026-02-18

> "the market split is still heavily weighted towards the overt population" — Scott Pescatore, Executive VP Rare Diseases, Full Year 2025 Results Conference Call, 2026-02-18

> "provide a solid foundation for sustainable and continued growth" — Andrea Recordati, Chairman, Annual Report 2025, on the Board and the Three-Year Plan


## Where a supplier can help

- **US rare disease patient finding**: The push to reach non-overt Cushing's syndrome patients with an expanded US field force and MSL team creates demand for diagnosis education, HCP targeting and patient services support.
- **Integration of licensed assets**: Frequent bolt-on licensing (Moderna, Ionis, Amarin) means repeated launch and integration work where regulatory, market access and commercial launch partners can help.
- **Digitalisation roadmap**: New IT systems, harmonised ways of working and AI in real-world evidence and clinical development point to openings for software, data and implementation suppliers.
- **Supply-chain resilience**: Reliance on over 150 contract manufacturers, tariff-driven inventory build and the Campoverde transformation give room for supply planning, logistics and plant engineering offers.
- **SPC cost efficiency**: With SPC flat and the commercial organisation right-sized, suppliers that improve commercial productivity or operating cost in European primary care fit the margin focus.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Annual Report 2025](https://dg0hkcpvy5xbq.cloudfront.net/wp-content/uploads/2026/04/12085946/ANNUAL-REPORT-2025_260508.pdf)

Annual report

- Recordati is a Milan-based pharmaceutical group, about 4,700 employees, present in around 150 countries, combining Specialty & Primary Care (58.7% of revenue) with a high-growth Rare Diseases business (41.3%).
- FY 2025 net revenue EUR 2,618.4 million (+11.8%, +8.3% like-for-like at constant exchange rates), EBITDA EUR 991.1 million (+14.5%, 37.8% margin), adjusted net income EUR 651.1 million (+14.5%), net income EUR 443.6 million.
- Rare Diseases grew 29.7% to EUR 1,081.4 million: Isturisa EUR 262.8 million after the April 2025 US label expansion to Cushing's syndrome (peak year sales now estimated above EUR 1.2 billion); Enjaymo (acquired from Sanofi) EUR 146.3 million.
- Specialty & Primary Care EUR 1,477.9 million (+2.0%): urology, cardiovascular, gastro-intestinal, cough and cold and consumer brands across Europe, Russia/CIS and Türkiye; about 90 commercial roles cut in Italy and Spain.
- The US is the largest market (20.1% of pharmaceutical revenue, +31.6%); Italy is 12.6% and declining.
- Business development: Vazkepa licensed from Amarin (59 countries), Inrebic for Japan, and mRNA-3927 from Moderna (January 2026); strategy is organic growth plus bolt-on M&A.
- 2026 guidance: revenue EUR 2,730-2,800 million, EBITDA EUR 995-1,030 million; 2027 targets revenue EUR 3,000-3,200 million and EBITDA EUR 1,140-1,225 million.
- Risks: FX (Turkish lira, US dollar), pricing and access pressure, geopolitical exposure (Russia, Türkiye), manufacturing and supply chain, cyber.
- CVC Capital Partners funds held 46.8% at end-2025; net debt EUR 2,037.3 million, just below 2.1x EBITDA.

### [Interim Report First Half 2026](https://dg0hkcpvy5xbq.cloudfront.net/wp-content/uploads/2026/07/01124804/ENG_Recordati-Group-Interim-report-First-Half-2026_WEB.pdf)

Interim report · 2026-07-28

- H1 2026 net revenue EUR 1,410.8 million, +6.6% (+9.1% like-for-like at constant exchange rates); FX headwind EUR 34.5 million.
- EBITDA EUR 540.2 million (+8.8%, 38.3% margin); adjusted net income EUR 349.9 million (+6.7%); net income EUR 269.7 million (+24.8%).
- Rare Diseases EUR 603.9 million (+17.1%): Isturisa EUR 178.8 million (+58.0%), Enjaymo EUR 91.0 million (+31.1%); Metabolic -8.0%.
- Specialty & Primary Care flat at EUR 773.5 million: loss of the Cardicor licence and a weak cough and cold season offset promoted-portfolio growth.
- US sales EUR 312.4 million (+29.5%); Italy -8.5%, Germany -6.6%, Spain +12.2%, Türkiye +16.2%.
- New licence from Ionis for zilganersen (Alexander disease, ex-US); pasireotide Phase 2 met its endpoint; sutimlimab Phase 3 in ITP from early 2027.
- CVC Fund IX and GBL launched a tender offer on 22 May 2026 to delist Recordati; acceptance period 31 August-15 October 2026.
- Net debt EUR 1,917.1 million (below 1.9x EBITDA); FY 2026 guidance confirmed.

### [First Nine Months 2026 Results press release](https://dg0hkcpvy5xbq.cloudfront.net/wp-content/uploads/2026/11/10160940/Press-Release_9M-2026-Results.pdf)

Interim report · 2026-11-10

- 9M 2026 net revenue EUR 2,103.7 million, +7.5% (+9.4% like-for-like at constant exchange rates); EBITDA EUR 801.1 million (+7.7%, 38.1% margin); adjusted net income EUR 524.9 million (+6.4%).
- Rare Diseases EUR 928.2 million (+18.7%): Isturisa EUR 285.9 million (+54.8%), Enjaymo EUR 135.2 million (+30.0%), Qarziba EUR 125.5 million.
- Specialty & Primary Care EUR 1,135.5 million (+0.5%); promoted portfolio in-market +8.4%.
- Free cash flow EUR 459.8 million; net debt EUR 1,697.8 million, around 1.6x EBITDA.
- Tender offer by CVC Fund IX and GBL closed 9 November 2026 with about 91.451% of the capital; squeeze-out of the remaining ~8% and delisting from Euronext Milan expected by end November; offer price EUR 53 per share.
- Recordati is now under the management and coordination of Respighi TopCo S.à r.l.; no 2026 interim dividend and no results call.
- FY 2026 guidance confirmed at the upper end of the ranges; 2027 targets unchanged.

### [Full Year 2025 Results Conference Call transcript](https://dg0hkcpvy5xbq.cloudfront.net/wp-content/uploads/2026/02/19094706/Recordati-FY-Results-2025-Transcript.pdf)

Executive talk · Rob Koremans, Chief Executive Officer · 2026-02-18

- CEO Rob Koremans and new CFO Mike McClellan presented FY 2025: revenue EUR 2.62 billion (+11.8%), EBITDA EUR 991 million at a 37.8% margin, free cash flow EUR 559 million.
- Isturisa closed 2025 with around 1,400 net active US patients; the US field force and MSL team are being expanded to reach non-overt Cushing's syndrome patients.
- Peak year sales of EUR 1.2 billion for Isturisa reaffirmed, already excluding China, where investment stopped after reimbursement was denied.
- Moderna's mRNA-3927 (propionic acidemia) could generate revenues from early '28 if data are positive; no 2026 EBITDA impact.
- 2026 guidance: revenue EUR 2.73-2.8 billion, Rare Diseases high-teen organic growth, SPC low single-digit, FX about -3.5%.
- Türkiye granted a 17% average price increase in January 2026; SPC reference markets slowed to about 3-4% growth.
- US inventory built ahead of potential tariffs covers the majority of 2026 sales; M&A "remains crucial"; no discovery or very high-risk R&D.

### [First Quarter 2026 Results Conference Call transcript](https://dg0hkcpvy5xbq.cloudfront.net/wp-content/uploads/2026/05/14112834/Recordati-Q1-2026-Transcript.pdf)

Executive talk · Robert Koremans, Chief Executive Officer · 2026-05-13

- Q1 2026 revenue EUR 730 million (+4.9%, +8.7% like-for-like); EBITDA EUR 284 million at a 39.7% margin.
- Isturisa up 56.8%; US field force and MSL expansion completed; more than 110 new prescribers added in Q1, mostly in the community; non-overt patients around 20% of the treated population.
- Pasireotide Phase 2 in post-bariatric hypoglycaemia met its primary endpoint; PBH peak sales kept at about EUR 150 million.
- Sutimlimab to start a pivotal Phase 3 in around 200 refractory ITP patients at the beginning of 2027.
- Extra Isturisa investment of EUR 40-50 million in 2026 reaches full speed in H2.
- Koremans: 2026 is secure from potential US tariffs thanks to inventory build; M&A strategy unchanged, possibly "stepping up seriously"; no comment on CVC.

### [First Half 2026 Results Conference Call transcript](https://dg0hkcpvy5xbq.cloudfront.net/wp-content/uploads/2026/07/01115612/Recordati-H1-2026-Results-Transcript.pdf)

Executive talk · Rob Koremans, Chief Executive Officer · 2026-07-29

- H1 2026 revenue EUR 1.4 billion (+6.6%, +9.1% like-for-like); EBITDA EUR 540 million at 38.3%; Koremans: rare disease "continues to be the key engine of our growth."
- Isturisa grew 58%; conversions from enrolment to active patients rose more than 20% versus Q1 as insurance churn eased.
- Expansion of US customer-facing teams completed; zilganersen licensed from Ionis (no guidance, ultra-rare disease).
- SPC broadly stable: Cardicor loss, Vazkepa EUR 14 million in H1, Eligard temporarily the only ADT in Türkiye.
- Germany down 6.6% on the deliberate exit from low-margin tenders; SPC commercial right-sizing largely done.
- Koremans declined to discuss the CVC/GBL tender offer beyond the published offer document; FY 2026 and 2027 targets confirmed.

## Questions about Recordati

### What does Recordati do?

Recordati is a Milan-based pharmaceutical group that sells specialty and primary care brands across Europe, Russia/CIS, Türkiye and North Africa, and rare disease treatments worldwide, including Isturisa and Enjaymo.

### What is Recordati's revenue?

FY 2025 net revenue was EUR 2,618.4 million, up 11.8%, with EBITDA of EUR 991.1 million. For the first nine months of 2026 revenue was EUR 2,103.7 million, and FY 2026 guidance is EUR 2,730-2,800 million.

### How many employees does Recordati have?

Recordati had 4,693 employees at year-end 2025 and is present in around 150 countries.

### Who owns Recordati?

A tender offer by CVC Fund IX and GBL closed on 9 November 2026 with about 91.451% of the capital at EUR 53 per share; a squeeze-out and delisting from Euronext Milan were expected by the end of November 2026.

### Who leads Recordati?

Rob Koremans is CEO, Andrea Recordati is Chairman and Mike McClellan has been Group CFO since 1 January 2026.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
